ARQT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

109.83M

+53.91%

0.076

-184.12%

98.23M

+49.18%

0.033

-116.67%

111.38M

+36.65%

0.110

-184.62%

Estimates Revision

The market is revising Upward the revenue expectations for Arcutis Biotherapeutics, Inc. (ARQT) for FY2025, with the revenue forecasts being adjusted by 7% over the past three months. During the same period, the stock price has changed by 40.75%.

Revenue Estimates for FY2025

Revise Upward

+7%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-66.54%

In Past 3 Month

Stock Price

Go Up

+40.75%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ARQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 28.67 USD with a low forecast of 21.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

28.67

High

32.00

Current: 0.000

Low

21.00

Averages

28.67

High

32.00

Mizuho

Uy Ear

Outperform

maintain

$32 -> $37

2025-11-28

Reason

Mizuho

Uy Ear

Price Target

$32 -> $37

2025-11-28

maintain

Outperform

Reason

Mizuho analyst Uy Ear raised the firm's price target on Arcutis Biotherapeutics to $37 from $32 and keeps an Outperform rating on the shares. With one month remaining in Q4, Zoryve prescription trends have been stronger than expected, the analyst tells investors in a research note. The firm upped its Q4 sales estimate to $113M, above the $110M consensus, and 2026 estimate to $470M, above the $467M consensus. Mizuho also has greater confidence in the potential of Zoryve to convert the steroidal market.

Goldman Sachs

Richard Law

Neutral

maintain

$19 -> $29

2025-10-30

Reason

Goldman Sachs

Richard Law

Price Target

$19 -> $29

2025-10-30

maintain

Neutral

Reason

Goldman Sachs analyst Richard Law raised the firm's price target on Arcutis Biotherapeutics to $29 from $19 and keeps a Neutral rating on the shares. Arcutis announced Q3 results and hosted an Investor Day to present more information on its three growth pillars that could potentially drive Zoryve's peak sales to $2.6B-$3.5B per annum, the analyst tells investors in a research note. Goldman's updated model assumes sustained growth without the need for future capital raises.

Mizuho

NULL -> Outperform

maintain

$26 -> $32

2025-10-29

Reason

Mizuho

Price Target

$26 -> $32

2025-10-29

maintain

NULL -> Outperform

Reason

Mizuho raised the firm's price target on Arcutis Biotherapeutics to $32 from $26 and keeps an Outperform rating on the shares.

H.C. Wainwright

Douglas Tsao

Buy

maintain

$22 -> $30

2025-10-29

Reason

H.C. Wainwright

Douglas Tsao

Price Target

$22 -> $30

2025-10-29

maintain

Buy

Reason

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Arcutis Biotherapeutics to $30 from $22 and keeps a Buy rating on the shares. The company reported strong Q3 results as Zoryve again beat expectations, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$19 -> $22

2025-08-07

Reason

H.C. Wainwright

Price Target

$19 -> $22

2025-08-07

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Arcutis Biotherapeutics to $22 from $19 and keeps a Buy rating on the shares following the Q2 report.

TD Cowen

Buy

maintain

$20 -> $25

2025-08-07

Reason

TD Cowen

Price Target

$20 -> $25

2025-08-07

maintain

Buy

Reason

TD Cowen raised the firm's price target on Arcutis Biotherapeutics to $25 from $20 and keeps a Buy rating on the shares. The firm notes total product sales beat consensus, with management reporting 19% quarter-to-quarter prescription growth, and GTN remains stable in the 50% range. Near-term growth will be driven by commercial execution and indication expansion. Zoryve life-cycle management and a focused subset of 40-plus possible inflammatory derm indications support mid-term growth, with pipeline and BD fueling long-term gains, TD Cowen adds.

Valuation Metrics

The current forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT.O) is 76.52, compared to its 5-year average forward P/E of -7.48. For a more detailed relative valuation and DCF analysis to assess Arcutis Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.48

Current PE

76.52

Overvalued PE

21.11

Undervalued PE

-36.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.82

Current EV/EBITDA

36.18

Overvalued EV/EBITDA

24.40

Undervalued EV/EBITDA

-46.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

102.48

Current PS

8.08

Overvalued PS

280.15

Undervalued PS

-75.20

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ARQT News & Events

Events Timeline

No data

News

9.5

01-06NASDAQ.COM

Arcutis' ZORYVE Revenue Reaches $244.6M in 2025 YTD, Anticipates $470M for 2026

4.5

2025-12-31NASDAQ.COM

Sprott Silver Miners ETF Declines 2.3% with Americas Gold and Vizsla Silver Underperforming

6.5

2025-12-23Fool

Suvretta Capital Reduces Arcutis Stake by $35.78 Million

People Also Watch

Frequently Asked Questions

What is Arcutis Biotherapeutics Inc (ARQT) stock price today?

The current price of ARQT is 28.22 USD — it has decreased -5.56 % in the last trading day.

What is Arcutis Biotherapeutics Inc (ARQT)'s business?

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

What is the price predicton of ARQT Stock?

What is Arcutis Biotherapeutics Inc (ARQT)'s revenue for the last quarter?

Arcutis Biotherapeutics Inc revenue for the last quarter amounts to 99.22M USD, increased 121.69 % YoY.

What is Arcutis Biotherapeutics Inc (ARQT)'s earnings per share (EPS) for the last quarter?

Arcutis Biotherapeutics Inc. EPS for the last quarter amounts to 0.06 USD, decreased -118.18 % YoY.

What changes have occurred in the market's expectations for Arcutis Biotherapeutics Inc (ARQT)'s fundamentals?

How many employees does Arcutis Biotherapeutics Inc (ARQT). have?

Arcutis Biotherapeutics Inc (ARQT) has 342 emplpoyees as of January 10 2026.

What is Arcutis Biotherapeutics Inc (ARQT) market cap?

Today ARQT has the market capitalization of 3.46B USD.